SanaCurrents is closing its position in Antibe this week, due to strong share performance and lack of clarity on key data. In the past year, Antibe Therapeutics (ATE:CN) (OTCQB: ATBPF) ($0.48, $145.5m market cap) delivered solid progress on the phase IIb efficacy […]
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only
This content is for members only